Introduction: The aim of this survey is to determine the pattern of antipsychotic drug use in patients with psychotic disorders, living in board and care facilities and to investigate the related factors.
In Turkey, APPP studies are generally performed in wards or outpatient clinics during maintenance treatment periods. Institutional studies were not found in the literature for Turkey. In this study, we aim to evaluate antipsychotic drug use pattern in people with psychotic disorder living in board and care facilities in Turkey.
METHODS
The patients admitted to the Sivas Numune Hospital psychiatry outpatient clinic for examination or control visit during November 1, 2012-May 31, 2013, the patients who stayed in board and care facilities, and the patients with psychotic disorders according to the Diagnostic and Statistical Manual of Mental Disorders, Forth edition (26) were included in the study. All patients had used APDs for at least for one month. The association between antipsychotic use pattern and demographic features and diagnosis was evaluated. Use of more than one APD for at least one month at a specified dosage range was considered as APPP use. APDs that were considered were Olanzapin 5 mg, ketiapin 200 mg, risperidon 2 mg, haloperidol 5 mg, klorpromazin 200 mg and above. Cumhuriyet University Medicine Faculty Ethical Committee approved the study (decision number: 2013-03/47). Sivas Numune Hospital Administration approved the required documents. Information regarding the study was given to patients and legal consultants, and their written informed consent forms were received.
Statistical Analysis
Data were evaluated with Statistical Package for the Social Sciences (SPSS Inc., Chicago, IL, USA) 16.0 program. Chi-square test was used for categorical comparisons of the groups; t test was used to compare mean values. P<0.05 was considered as significant.
RESULTS
Two hundred patients staying in board and care facilities were evaluated. The demographic characteristics and clinical characteristics of the patients and associations with mono or polytherapy use were presented in Table 1 .
The ratio of APMT use was 38%, use of two APDs was 34%, and use of more than two APDs was 28% (Table 2 ). Sixty-one percent patients used biperiden plus antipsychotic drugs, 15% patients used low dose clorpromazin plus antipsychotic drugs, and 8% patients used mood-stabilizer drugs plus antipsychotics.
Olanzapine is the most preferred drug for monotherapy, followed by quetiapine and risperidone (Table 3) . Although 28% of patients with monotherapy used biperiden, patients with polytherapy who used four to five APDs used biperiden at a rate of 100% (Table 3,4).
35% of the patients used depot APDs (n=69, Zuc=53, Ris=14, Flu=2); however, 7% of them used monotherapy (Table 3, 4, 5, 6) . The most preferred doublet APD was olanzapin-ketiapin combination (13%). The incidence of first and second generation APD use was 50% (n=34), second generation APD combination use was 44% (n=30), and doublet use of first generation APD was 4% (n=3) ( Table 5 ).
The incidence of clozapine use was 3% (4 APMT, 2 APPP) (Table 3,5,6). Low rate of clozapine combination is remarkable as preferred too few in polytherapy. Polytherapy drugs mentioned in Table 4 and 6 are examples of the overdose of APD. In addition, it is remarkable that the frequency of APPP administration increased as the depot APD administration increased.
DISCUSSION
According to the study results, 62% of the patients with psychotic disorder living in board and care facilities have used multiple antipsychotic drugs. APPP use was determined as common in young patients, suicide attempt cases, frequently hospitalized patients, patients with higher Clinical Overall Impression scores, and patients with schizophrenia and schizoaffective disorders. Olanzapine-quetiapine was the most preferred combination as a doublet APD, and olanzapine was the most preferred agent for single APD use. Typical-atypical APD combination was the most preferred combination (50%) as a doublet APD. Depot APDs were frequently used with other APDs. Single depot APD was rarely used. Anticholinergic drug requirement was increased if several APD agents were used. According to studies performed in our country with hospitalized and outpatient schizophrenia patients, the prevalence of APPP use is 38-74% (16, 17, 18, 19, 20, 27, 28, 29) . APPP use is common almost in every clinical practice. Use of two and more APDs combination is common worldwide for the treatment of schizophrenia and other psychotic disorders (14, 30, 31) . Treatment guidelines never recommend the use of antipsychotic polypharmacy initially; therefore, we should attempt to understand the reason for clinicians prescribing APPP so commonly.
The major indication of common APPP use is probably the clinical severity. However, according to previous studies, clinical severity is valid factor only for the hospitalized patients and not for outpatients (5, 20, 32) . APPP does not increase antipsychotic effect or does not decrease clinical severity more than APMT. Furthermore, APPP causes more side effects (33, 34) . In our study, APPP use was common in young patients, suicide attempt cases, and frequently hospitalized patients; therefore, it may be directly associated with the overall clinical severity. However, we do not have any evidence that shows that APPP use is a solution for clinical severity. In our study, we were unable to determine whether appropriate APMT dose was used. Six out of 161 schizophrenia patients (3%) had used clozapine. Only four of these six patients had already used monotherapy. Therefore, we can conclude that this clinical practice is not consistent with the scientific recommendations.
Antipsychotic polypharmacy use was 62% in our sample, and was not consistent with the treatment algorithm recommendations. Treatment algorithms generally recommend using APPP after clozapine trials. While four of 76 APMT patients used clozapine, only two of 124 APPP patients with psychotic disorder used clozapine. These results show that clozapine is not appropriately used in clinical settings. However, clozapine plus another APD is recommended as combination therapy in treatment algorithms, and usually preferred in some clinical settings (8, 25, 35) . According to another study performed in Turkey (20) , clozapine is used rarely (7%), and is not included in APPP regimes. In general, we can conclude that sufficient dose of APMT, at least clozapine, is not administered in APPP patients and treatment algorithms are not followed. If APPP is preferred, the most compatible APDs should be combined. Given the cost-expense profile and side effect risk, more than two APD may be more harmful to patients. APPP are generally administered in higher (over) dosages, and therefore, increases the side effects as compared with APMT (1,5). In conclusion, treatment guidelines suggest that multiple antipsychotics should be the last choice in resistant patients, and they may be used for a short time during antipsychotic switching. However, we observed that multiple antipsychotics are preferred frequently in our sample patients staying in board and care facilities. Our study is the first APD use pattern study performed in this patient population. More than onefourth of these patients had used more than two APDs at the same time. In our study, the disease was more severe in the APPP group. Even though multiple antipsychotic drug use increase the risk of side effects, and more drugs are needed to relieve side effects, drug-drug interactions increase, treatment compliance impairs, and mortality rate increases (14) , polypharmacy is used increasingly. Controlled studies are required to elucidate the reasons and to solve the problems regarding polypharmacy. However, the studies show that APPP is used without enough APMT trial period at sufficient dosages (30, 36) . APPP in outpatient group has not been predicted at psychopathology levels (37) . Twothird of the patients did not experience psychopathology alterations, and furthermore, the incidence of weight gain decreased when APPP use switched to APMT use (38) . We should clarify the reason for the clinicians preferring APPP so easily, and educate doctors to be careful and avoid prescription of hazardous APPP.
In our study, the data were obtained from patients, patient files, and hospital attendants. Therefore, the most important limitation of our study was access some information. The other limitations were that we could not evaluate side effects associated with drugs, and we could not understand the reasons of prescribing polypharmacy. 
